Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scarmeas, N.
Right arrow Articles by Stern, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scarmeas, N.
Right arrow Articles by Stern, Y.
Related Collections
Right arrow All Neuropsychology/Behavior
Right arrow Alzheimer's disease
Neurology 2002;58:1182-1188
© 2002 American Academy of Neurology

Association between the APOE genotype and psychopathologic symptoms in Alzheimer’s disease

N. Scarmeas, MD, J. Brandt, PhD, M. Albert, PhD, D. P. Devanand, MD, K. Marder, MD MPH, K. Bell, MD, A. Ciappa, MD, B. Tycko, MD PhD and Y. Stern, PhD

From the Cognitive Neuroscience Division (Drs. Scarmeas and Stern), Taub Institute for Research in Alzheimer’s Disease and the Aging Brain, and Departments of Neurology (Drs. Scarmeas, Marder, Bell, and Stern), Psychiatry (Drs. Devanand and Stern), and Pathology (Drs. Ciappa and Tycko), and Gertrude H. Sergievsky Center (Drs. Scarmeas, Devanand, Marder, Bell, and Stern), Columbia University College of Physicians and Surgeons, New York, NY; Department of Psychiatry and Behavioral Sciences (Dr. Brandt), Johns Hopkins University, Baltimore, MD; and Departments of Psychiatry and Neurology (Dr. Albert), Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Address correspondence and reprint requests to Dr. Yaakov Stern, Gertrude H. Sergievsky Center, 630 W. 168 St., New York, NY 10032; e-mail: ys11{at}columbia.edu

Background: Psychiatric symptoms occur frequently in the course of AD, are a frequent contributor to institutionalization, predict cognitive decline and death, and often require treatment with psychotropic medications. Previous studies investigating the association between APOE genotype and psychiatric symptomatology in AD have reported contradictory results.

Objective: To determine whether APOE genotype predicts incident psychiatric symptomatology in patients with AD.

Methods: Eighty-seven patients with AD at early stages and no psychiatric history were followed semiannually for up to 9.3 years (mean 5.5 years) for development of delusions, illusions, hallucinations, behavioral symptoms, and depression. Cox proportional hazards models were used to examine the relative risk for incident psychiatric symptomatology (outcome) in relation to APOE genotype (predictor).

Results: The presence of one {epsilon}4 allele carried a 2.5-fold risk, whereas the presence of two {epsilon}4 alleles carried a 5.6-fold risk for development of delusions. The associations remained significant even when age, ethnicity, sex, education, duration of disease, and cognitive and functional performance were controlled for. The presence of two {epsilon}4 alleles was associated with reduced risk for developing hallucinations in the adjusted analysis only. No significant associations were detected between APOE genotype and the incidence of illusions, behavioral symptoms, or depression.

Conclusion: The presence of one or more {epsilon}4 alleles is a significant predictor for the incidence of delusions in the course of AD.




This article has been cited by other articles:


Home page
Epidemiol RevHome page
J. J. Jalbert, L. A. Daiello, and K. L. Lapane
Dementia of the Alzheimer Type
Epidemiol. Rev., July 16, 2008; (2008) mxn008v1.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
N. Scarmeas, J. A. Luchsinger, R. Mayeux, and Y. Stern
Mediterranean diet and Alzheimer disease mortality
Neurology, September 11, 2007; 69(11): 1084 - 1093.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
A L Pritchard, J Harris, C W Pritchard, J Coates, S Haque, R Holder, P Bentham, and C L Lendon
The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry, February 1, 2007; 78(2): 123 - 126.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. W. Zhu, N. Scarmeas, R. Torgan, M. Albert, J. Brandt, D. Blacker, M. Sano, and Y. Stern
Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease
Neurology, September 26, 2006; 67(6): 998 - 1005.
[Abstract] [Full Text] [PDF]


Home page
J Geriatr Psychiatry NeurolHome page
D. V. Jeste, T. W. Meeks, D. S. Kim, and G. S. Zubenko
Research Agenda for DSM-V: Diagnostic Categories and Criteria for Neuropsychiatric Syndromes in Dementia
J Geriatr Psychiatry Neurol, September 1, 2006; 19(3): 160 - 171.
[Abstract] [PDF]


Home page
NeurologyHome page
C. W. Zhu, N. Scarmeas, R. Torgan, M. Albert, J. Brandt, D. Blacker, M. Sano, and Y. Stern
Clinical features associated with costs in early AD: Baseline data from the Predictors Study
Neurology, April 11, 2006; 66(7): 1021 - 1028.
[Abstract] [Full Text] [PDF]


Home page
AJGPHome page
B. Borroni, M. Grassi, C. Agosti, S. Archetti, C. Costanzi, C. Cornali, C. Caltagirone, L. Caimi, M. Di Luca, and A. Padovani
Cumulative Effect of COMT and 5-HTTLPR Polymorphisms and Their Interaction With Disease Severity and Comorbidities on the Risk of Psychosis in Alzheimer Disease
Am J Geriatr Psychiatry, April 1, 2006; 14(4): 343 - 351.
[Abstract] [Full Text] [PDF]


Home page
AM J ALZHEIMERS DIS OTHER DEMENHome page
L. C. Lam, N. L. Tang, S. Ma, V. W. Lui, A. S. Chan, P Y Leung, and H. F. Chiu
Apolipoprotein epsilon-4 allele and the two-year progression of cognitive function in Chinese subjects with late-onset Alzheimer's disease
American Journal of Alzheimer's Disease and Other Dementias, March 1, 2006; 21(2): 92 - 99.
[Abstract] [PDF]


Home page
NeurologyHome page
N. Scarmeas, M. Albert, J. Brandt, D. Blacker, G. Hadjigeorgiou, A. Papadimitriou, B. Dubois, M. Sarazin, D. Wegesin, K. Marder, et al.
Motor signs predict poor outcomes in Alzheimer disease
Neurology, May 24, 2005; 64(10): 1696 - 1703.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
N. Scarmeas, G. M. Hadjigeorgiou, A. Papadimitriou, B. Dubois, M. Sarazin, J. Brandt, M. Albert, K. Marder, K. Bell, L. S. Honig, et al.
Motor signs during the course of Alzheimer disease
Neurology, September 28, 2004; 63(6): 975 - 982.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
J. B. Chang, P. N. Wang, W. T. Chen, C. Y. Liu, C. J. Hong, K. N. Lin, T. Y. Liu, C. W. Chi, and H. C. Liu
ApoE {epsilon}4 allele is associated with incidental hallucinations and delusions in patients with AD
Neurology, September 28, 2004; 63(6): 1105 - 1107.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
N. Scarmeas, K. E. Anderson, J. Hilton, A. Park, C. Habeck, J. Flynn, B. Tycko, and Y. Stern
APOE-dependent PET patterns of brain activation in Alzheimer disease
Neurology, September 14, 2004; 63(5): 913 - 915.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.